| 摘要: |
| 目的:探讨喜炎平联合阿奇霉素治疗小儿重症肺炎支原体肺炎的临床疗效及其对免疫功能的影响。方法:选取2014年1月至2016年6月我院收治的重症肺炎支原体肺炎患儿80例,采用随机数字表法分为观察组和对照组各40例,两组患儿均给予常规治疗及阿奇霉素治疗,观察组在对照组治疗基础上加用喜炎平治疗,比较两组患儿临床疗效、临床症状改善情况及治疗前后T淋巴细胞亚群指标(CD3+、CD4+、CD8+、CD4+/CD8+)水平。结果:观察组治疗总有效率95郾0%,显效率85.0%,高于对照组的85.0%及67.5%,观察组患儿退热时间(4.27±1.56)d、咳嗽消失时间(8.12±2.02)d、啰音消失时间(4.84±1.62)d、胸片吸收时间(10.86±1.87)d,均短于对照组的(5.16±1.82)d、(9.35±2.62)d、(5.63±1.53)d、(13.28±2.49) d;治疗后两组患儿CD3+、CD4+、CD4+/CD8+均升高,CD8+降低,但观察组上述指标改善程度优于对照组,差异有统计学意义(P<0.05)。结论:喜炎平联合阿奇霉素治疗小儿重症肺炎支原体肺炎能增加临床疗效、改善患儿临床症状,调节患儿细胞免疫功能。 |
| 关键词: 喜炎平 重症 肺炎支原体肺炎 免疫功能 |
| DOI：doi: 10.13407/j.cnki.jpp.1672-108X.2017.12.009 |
|
| 基金项目: |
|
| Curative Effect of Xiyanping Combined with Azithromycin in the Treatment of Severe Mycoplasma Pneumoniae Pneumonia in Children |
| Liu Maohua, Liu Chengjun, Yu Fengfei, Li Xingli |
| (Central Hospital of Linyi Province, Shandong Linyi 276000, China) |
| Abstract: |
| Objective: To investigate the therapeutic effects and immune function of Xiyanping combined with azithromycin in treatment of severe Mycoplasma pneumoniae pneumonia (MPP) in children. Methods: Eighty severe MPP children treated in our hospital From January 2014 to June 2016 were selected, randomly divided into observation group and control group, 40 cases in each group. While the control group was given azithromycin treatment, the observation group was given azithromycin and Xiyanping injection. The clinical
effects and the clinical symptoms of the two groups were compared. The T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+) were compared between the two groups before and after treatment. Results: The total effective rate was 95.0% in the observation group, the markedly effective rate was 85.0%, higher than 85.0% and 67.5% of the control group. Defervescence time (4.27±1.56)d, cough disappeared time (8.12±2.02)d, rales disappearance time (4.84±1.62) d and chest X-ray absorption time (10.86±1.87) d in
observation group were significantly shorter than the control group (5.16±1.82)d, (9.35±2.62)d, (5.63±1.53)d, (13.28±2.49)d. The differences were significant (P<0.05). Compared with before treatment, the levels of CD3+, CD4+, CD4+/CD8+ were significantly increased in the two groups after treatment, while CD8+ decreased significantly. But the improvement degrees of the observation group were significantly better than the control group. The differences were significant (P<0.05). Conclusion: Xiyanping combined with azithromycin in treatment of Mycoplasma pneumoniae pneumonia in children can significantly improve clinical symptoms, improve the clinical symptoms and regulate immune function in children. |
| Key words: Xiyanping severe Mycoplasma pneumoniae pneumonia immune function |
